Position in GANX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,149,243
+$50,951 QoQ
Shares Held
566,130
0.0% QoQ
Ownership
1.30%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#6
of 49 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DME Capital Management, LP holds $109,269,925 across 6 Biotechnology names. GANX ranks #5 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
2,152,669 | $76,182,954 | |
| 2 | LKFT |
Lakefront Biotherapeutics NV
|
482,746 | $14,472,724 | |
| 3 | COYA |
Coya Therapeutics, Inc.
|
2,335,540 | $13,662,908 | |
| 4 | IMVT |
Immunovant, Inc.
|
93,520 | $3,603,325 | |
| 5 | GANX |
Gain Therapeutics, Inc.
This page
|
566,130 | $1,149,243 | |
| 6 | NUVB |
Nuvation Bio Inc.
|
34,995 | $198,771 |
All Filings in GANX
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,149,243 | 566,130 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $1,098,292 | 566,130 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $1,822,938 | 566,130 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,002,050 | 566,130 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $1,019,034 | 566,130 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,081,308 | 566,130 | Shares | Other | 2025-05-15 | |
| 2024-12-31 | $1,222,840 | 566,130 | Shares | Other | 2025-02-14 | |
| 2024-09-30 | $1,007,711 | 566,130 | Shares | Other | 2024-11-14 | |
| 2024-06-30 | $724,646 | 566,130 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $2,134,310 | 566,130 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||